Phenotypes associated with this allele

• Allele Symbol: Dhps^{tm2c(EUCOMM)Wtsi}
• Allele Name: targeted mutation 2c, Wellcome Trust Sanger Institute
• Allele ID: MGI:5812110
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Dhps^tm2c(EUCOMM)Wtsi/Dhps^tm2c(EUCOMM)Wtsi Tg(CAG-cre/Esr1*)5Amc/0	involves: C57BL/6J * C57BL/6N * CBA * SJL	MGI:5903287

Genotype
MGI:5903287

cn1

• Allelic Composition: Dhps^{tm2c(EUCOMM)Wtsi}/Dhps^{tm2c(EUCOMM)Wtsi}; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: C57BL/6J * C57BL/6N * CBA * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:236582 )

• 5 to 14 days after tamoxifen treatment

hematopoietic system

decreased bone marrow cell number ( J:236582 )

• of all three cell lines after tamoxifen treatment

decreased spleen red pulp amount ( J:236582 )

• after tamoxifen treatment

spleen hypoplasia ( J:236582 )

• after tamoxifen treatment

growth/size/body

decreased body weight ( J:236582 )

• in tamoxifen-treated mice

cachexia ( J:236582 )

• in tamoxifen-treated mice due to wasting syndrome

renal/urinary system

increased kidney iron level ( J:236582 )

• enhanced ferrous iron incorporation in the kidney of 2 of 4 tamoxifen-treated mice

homeostasis/metabolism

increased kidney iron level ( J:236582 )

• enhanced ferrous iron incorporation in the kidney of 2 of 4 tamoxifen-treated mice

immune system

decreased spleen red pulp amount ( J:236582 )

• after tamoxifen treatment

spleen hypoplasia ( J:236582 )

• after tamoxifen treatment